316 related articles for article (PubMed ID: 34987657)
21. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
[TBL] [Abstract][Full Text] [Related]
23. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
[TBL] [Abstract][Full Text] [Related]
24. A Simple Kit Formulation for Preparation and Exploratory Human Studies of a Novel
Ruan Q; Zhou C; Wang Q; Kang F; Jiang Y; Li G; Feng J; Zong S; Zhang J; Wang J
Mol Pharm; 2023 Jun; 20(6):2942-2950. PubMed ID: 37083360
[TBL] [Abstract][Full Text] [Related]
25. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
26. A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging.
Zhao X; Zhang G; Chen J; Li Z; Shi Y; Li G; Zhai C; Nie L
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1593-1604. PubMed ID: 38512485
[TBL] [Abstract][Full Text] [Related]
27. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Ding J; Xu M; Chen J; Zhang P; Huo L; Kong Z; Liu Z
Mol Pharm; 2022 Sep; 19(9):3429-3438. PubMed ID: 35976352
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Preliminary Study of
Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
[TBL] [Abstract][Full Text] [Related]
30. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
[TBL] [Abstract][Full Text] [Related]
31. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
[TBL] [Abstract][Full Text] [Related]
32.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
[TBL] [Abstract][Full Text] [Related]
35. Clinical translation of a novel FAPI dimer [
Tan Y; Li J; Zhao T; Zhou M; Liu K; Xiang S; Tang Y; Jakobsson V; Xu P; Chen X; Zhang J
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38561515
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of [
Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors.
Lindeman SD; Mukkamala R; Horner A; Tudi P; Booth OC; Huff R; Hinsey J; Hovstadius A; Martone P; Zhang F; Srinivasarao M; Cox A; Low PS
J Nucl Med; 2023 May; 64(5):759-766. PubMed ID: 37116911
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis and Preclinical Assessment of
Trujillo-Benítez D; Luna-Gutiérrez M; Ferro-Flores G; Ocampo-García B; Santos-Cuevas C; Bravo-Villegas G; Morales-Ávila E; Cruz-Nova P; Díaz-Nieto L; García-Quiroz J; Azorín-Vega E; Rosato A; Meléndez-Alafort L
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011496
[TBL] [Abstract][Full Text] [Related]
39. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
40. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Wang Z; Tian R; Niu G; Ma Y; Lang L; Szajek LP; Kiesewetter DO; Jacobson O; Chen X
Bioconjug Chem; 2018 Sep; 29(9):3213-3221. PubMed ID: 30105912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
